 |
Artemisinin or Qinghaosu ("ching-how-soo") is the active
principal of the Chinese medicinal herb Artemisia annua. It has been used as
treatment of fevers in China for more than 1000 years. The antimalarial value of
Artemisia annua was first documented in Zhou Hou Bei Ji Fang (Handbook of prescriptions for
emergency treatments) written as early as 340 AD by Ge Hong of the Eastern Jin Dynasty.
The active antimalarial constituent of this plant was isolated in 1971 and it was named
artemisinin. The WHO accorded high priority to the development of fast acting artemisinin
derivatives for the treatment of cerebral malaria as well as for the control of multi-drug
resistant P. falciparum malaria. A water soluble ester called artesunate and two
oil soluble preparations called artemether and arteether have now been developed. |
The
Artemisinin Derivatives
Anti malarial activity:
They act by inhibiting a P falciparum-encoded sarcoplasmic-endoplasmic reticulum
calcium ATPase, and not by inhibiting the haem metabolic pathway as previously supposed.
Most clinically important artemisinins are metabolised to dihydroartemisinin (elimination
half-life of about 45 min), in which form they have comparable antimalarial activity.
However, their use in monotherapy is associated with high incidences of recrudescent
infection, suggesting that combination with other antimalarials might be necessary for
maximum efficacy.
It is the fastest acting anti malarial
available. It inhibits the development of the trophozoites and thus prevents progression
of the disease. Young circulating parasites are killed before they sequester
in the deep microvasculature. These drugs starts acting within 12 hours. These
properties of the drug are very useful in managing complicated P. falciparum malaria.
These drugs are also effective against the chloroquine resistant strains of P. falciparum.
Artesunate and artemether have been shown to clear parasitaemias more
effectively than chloroquine and sulfadoxine/pyrimethamine. Meta
analysis of mortality in trials indicated that a patient treated with
artemether had at least an equal chance of survival as a patient treated
with quinine. It has also been reported that artemisinin drugs cleared
parasites faster than quinine in patients with severe malaria but fever
clearance was similar. Also, parenteral artemether and artesunate are
easier to use than quinine and do not induce hypoglycaemia.
Gametocytocidal action:
Artemisinin compounds have been reported to reduce gametocytogenesis,
thus reducing transmission of malaria, this fact being specially
significant in preventing the spread of resistant strains.
These drugs prevent the gametocyte development by their action on the
ring stages and on the early (stage I-III) gametocytes.[Mehra N, Bhasin
VK. In vitro gametocytocidal activity of artemisinin and its derivatives
on Plasmodium falciparum. Jpn J Med Sci Biol. 1993
Feb;46(1):37-43]. In studies including over 5000 patients in Thailand,
it was shown that gametocyte carriage was significantly less frequent
after treatment with artemisinin derivatives than after treatment with
mefloquine.
Absorption, fate and excretion:
Artemisinin derivatives are absorbed well after intra muscular or oral administration. The
drug is fully metabolised and the major metabolite is dihydroartemisinin, which also has
anti parasite effects. It is rapidly cleared, predominantly through the bile.
Toxicity: The drug is relatively
safe and it has not been found to have any teratogenic effects on the embryo in animal
studies. The adverse reactions reported from animal studies include neurotoxicity,
brainstem neuronal damage, and QTC prolongation. Drug induced pyrexia is also
seen.
Availability: Artemisinin is
available as its derivatives, artemether, artesunate and arteether. The ether derivatives
are more soluble in oil and are available as injections for intra muscular use. Artemether
is available as injection of 80 mg in 1 ml. Artemether capsules containing 40 mg of the
drug are also now available. Arteether is available as injection of 150 mg in 2 ml.
Artesunate is an ester derivative that is
more soluble in water. The drug is available as a powder. It should be first dissolved in
1 ml of 5% sodium bicarbonate (usually provided with the vial) and shaken for 2-3 minutes.
After it dissolves completely, it is diluted with 5% dextrose or saline (for intravenous
use, dilute with 5 ml and for intramuscular use, dilute with 2 ml). Intravenous dose
should be injected slowly at a rate of 3-4 ml/minute. It is also available as tablets,
each containing 50 mg of the drug.
Dose:
Artemether:
Available as 80mg/ml Injection and 40mg per capsule
Injection: 3.2 mg/kg intra
muscularly as a loading dose, followed by 1.6 mg/kg daily until oral therapy or a maximum
of 7 days.
Oral:
4mg/kg on first day followed by 2mg/kg for 6 days.
Arteether:
Available as 150mg per 2 ml ampoule
Dose: 3 mg/kg once a day for
3 days, as deep intra muscular injection.
Artesunate:
In India it is available as 50mg tablets and 60mg/ml injection. In
China it is also available as 100mg suppository and in Switzerland
is available as 200mg rectocap
Oral-
4 mg/kg on the
first day followed by 2mg/kg for 6 days. It can also be used in
combination; 4mg/kg on the second and third days with mefloquine 15 mg/kg in a
single dose on the second day. Oral artesunate is not recommended in pregnancy.
Parenteral- Loading dose of 2.4 mg/kg
followed by 2.4mg/kg after 12 hours, 24 hours and once daily thereafter for maximum of
7 days. For children, the recommended dose is 1.2 mg/kg/day for 5-7 days.
See
Artemisinin based combinations
Sources:
Day N,
Dondorp AM. The Management of Patients with Severe Malaria. Am. J.
Trop. Med. Hyg. 2007;77(Suppl 6):29–35 Available at
http://www.ajtmh.org/cgi/reprint/77/6_Suppl/29
|